Ionis Pharmaceuticals Inc (NASDAQ:IONS) has been on the market for over 26 years being the leader in the RNA-targeted therapeutic space. The company which changed its name from ISIS Pharmaceuticals (ISIS) in December 2015 has its primary focus on making available its late-stage drugs in the markets and developing new high-value medicines, which could be handy in the treatment of life-threatening diseases.
The company’s move is a plus for the market whose prices for high-value drugs are unsustainable. The performance of the current products as well new and existing collaborations are to blame for the stock prices and valuation that are above the ceiling. Other fundamental factors include the results of clinical trials and product approvals.
But the company’s revenue inclinations are changing
The biopharmaceutical company has so far developed a diverse pipeline for potentially best-in-class drugs. In fact, its broadly applicable drug discovery platform has played a significant role in meeting the unmet medical needs of a multitude of patients. However, its revenues still slid with over 68% to $38.5 million in 2Q16, compared to $120.4 million in 2Q15. But seemingly there is hope for an increase by over 100% to $114.8 million in 3Q16 according to the latest analysts estimate.
Of the $38.5 million, $15 million was an upfront payment from Kastle Therapeutics for the purchase of Kynamro. The research and development revenues stood at $22.4 million while licensing and royalty revenues rose to $16.0 million.
Ionis has new developments
The company entered a collaborative agreement with Biogen Inc (NASDAQ:BIIB) that will result in the development of Nusinersen. The drug, which has been classified as severe and rare therapeutic areas, is mainly designated for the treatment of patients with spinal muscular atrophy (or SMA). Nonetheless, it is in its Phase III study of infants and children with SMA having obtained the approvals from the US Food and Drug Administration and the European Medicines Agency.
Apart from this, the company is also in another partner alliance with GlaxoSmithKline plc (ADR) (NYSE:GSK) which will give birth to the development and commercialization of IONIS-TTR.